A study to find out if fezolinetant helps reduce moderate to severe hot flashes in women in Asia going through menopause

Trial Identifier: 2693-CL-0305
Sponsor: Astellas Pharma China, Inc.
Start Date: March 2020
Primary Completion Date: April 2022
Study Completion Date: April 2022

Available Languages

For questions about your Trial Results Summary, please see Sponsor contact section within your Trial Results Summary.

Language Description

Trial Locations

Country Location
China Beijing, China
China Changchun, China
China Changsha, China
China Chengdu, China
China Dalian, China
China Fuzhou, China
China Guangzhou, China
China Guiyang, China
China Hangzhou, China
China Kunming, China
China Lanzhou, China
China Liuzhou, China
China Nanjing, China
China Nanning, China
China Shanghai, China
China Shenzhen, China
China Shijiazhuang, China
China Suzhou, China
China Taiyuan, China
China Tianjin, China
China Wuhan, China
China Yangzhou, China
China Yinchuan, China
China Zhongshan, China
Korea (Republic of) Ansan-si, Korea (Republic of)
Korea (Republic of) Busan, Korea (Republic of)
Korea (Republic of) Seongnam-si, Korea (Republic of)
Korea (Republic of) Seoul, Korea (Republic of)
Taiwan, Province of China Kaohsiung City, Taiwan, Province of China
Taiwan, Province of China New Taipei City, Taiwan, Province of China
Taiwan, Province of China Putzu, Taiwan, Province of China
Taiwan, Province of China Taichung, Taiwan, Province of China
Taiwan, Province of China Tainan, Taiwan, Province of China
Taiwan, Province of China Taipei, Taiwan, Province of China